HAIC Combined With Durvalumab, Tremelimumab and Bevacizumab as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma
To evaluate the efficacy and safety of HAIC combined with Durvalumab, Tremelimumab and Bevacizumab as first-line therapy in Unresectable hepatocellular carcinoma
Unrescetable Hepatocellular Carcinoma
DRUG: HAIC+Durvalumab+Tremelimumab+Bevacizumab
Overall response rate ( ORR) per RECIST 1.1, Defined as proportion of patients who have a best response of CR or PR, Up to 1 year
Overall survival (OS), Defined as the time from enrollment to death from any cause, Up to two years|Progress Free Survival (PFS), Defined as the time from enrollment to disease progression or death (whichever occurs first), Up to two years|Disease Control Rate (DCR) per RECIST 1.1, Defined as proportion of patients who have CR or PR or SD, Up to one year|Duration of Response(DoR) per RECIST 1.1, The time from the first assessment of the tumor as CR or PR to the second assessment as PD (Progressive Disease) or death from any cause, Up to two years|Time To Progress(TTP) per RECIST 1.1, The time from the beginning to the first objective progression of the tumor, Up to two years
An open label, single-arm, single center, phase II study evaluating HAIC combined with Durvalumab, Tremelimumab and Bevacizumab as first-line therapy in unresectable hepatocellular carcinoma